GelStat Stock Price, News & Analysis (OTCMKTS:GSAC) $0.0004 +0.00 (+33.33%) (As of 04:30 PM ET) Add Compare Share Share Today's Range$0.0003▼$0.000450-Day Range N/A52-Week Range$0.0001▼$0.0018Volume2.74 million shsAverage Volume30.44 million shsMarket Capitalization$247,192.00P/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartFinancialsSEC FilingsShort InterestStock AnalysisChartFinancialsSEC FilingsShort Interest About GelStat Stock (OTCMKTS:GSAC)GelStat Corporation, a consumer health care company, engages in the research, development, and marketing of over-the-counter and other non-prescription consumer health care products. Its products include GelStat Migraine, a patented solution used for pain relief from migraine headaches; Chews 2 Lose, an appetite suppressant gum for diet aide; All Natural Speed, an energy supplement product; and GelStat Sleep, a product for relief from sleep disorders and its associated symptoms. The company sells its products to retailers, wholesalers, specialty distributors, and catalog merchandisers both directly and through external sales brokers. GelStat Corporation was founded in 2002 and is headquartered in Palm City, Florida.Read More GSAC Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart GSAC Stock News HeadlinesNovember 30, 2023 | americanbankingnews.comGelStat Corp. (OTCMKTS:GSAC) Short Interest Down 38.6% in NovemberSeptember 6, 2022 | marketwatch.comFunctional Chewing Gum Market 2022 | with COVID-19 Pandemic Analysis & Future Growth Analysis by prime Key Players and Regional Forecast 2026December 5, 2023 | DTI Trader (Ad)All the trading advice you’ve ever received boils down to thisAll the trading advice you’ve ever received boils down to one goal and one goal only: finding a reliable edge in the markets. If you can do that, grab hold of it and never let go. Because once you have that edge, and you can count on it, you never need to do anything else.August 26, 2022 | marketwatch.comFunctional Chewing Gum Market Is PoIsed to Reflect 5.3%% CAGR by 2027 | 111 Report PagesAugust 15, 2022 | reuters.comGSAC.PK - Gelstat Corp | Stock Price & Latest News | ReutersJune 2, 2022 | finance.yahoo.comGelStat Announces $5 Million Public Offering Under Regulation A+June 2, 2022 | finance.yahoo.comGelStat Provides Corporate Update on Capital RestructuringSee More Headlines Receive GSAC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for GelStat and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Today12/05/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolOTCMKTS:GSAC CUSIPN/A CIK890725 Webwww.gelstat.com Phone(772) 212-1368Fax888-512-3766Employees2Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding Shares617,980,000Free Float491,294,000Market Cap$247,192.00 OptionableNot Optionable Beta1.81 Elon Musk's Next MoveWondering when you'll finally be able to invest in SpaceX, StarLink or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.Get This Free Report Key ExecutivesMr. Javier G. AcostaCEO & DirectorMr. Charles F. Tarzian (Age 66)Chief Marketing Advisor Dr. Roger K. Cady M.D.Chief Medical AdvisorKey CompetitorsCalithera BiosciencesNASDAQ:CALAPropanc BiopharmaOTCMKTS:PPCBOrexigen TherapeuticsOTCMKTS:OREXQSunwin Stevia InternationalOTCMKTS:SUWNAdhera TherapeuticsOTCMKTS:ATRXView All Competitors GSAC Stock Analysis - Frequently Asked Questions How have GSAC shares performed in 2023? GelStat's stock was trading at $0.0009 on January 1st, 2023. Since then, GSAC stock has decreased by 55.6% and is now trading at $0.0004. View the best growth stocks for 2023 here. Are investors shorting GelStat? GelStat saw a decrease in short interest in the month of November. As of November 15th, there was short interest totaling 76,700 shares, a decrease of 38.6% from the October 31st total of 125,000 shares. Based on an average trading volume of 62,050,700 shares, the days-to-cover ratio is presently 0.0 days. View GelStat's Short Interest. How do I buy shares of GelStat? Shares of GSAC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. This page (OTCMKTS:GSAC) was last updated on 12/5/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding GelStat Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.